Revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
GSK plc (GSK)
Price£18.78Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | £32.67B | £31.38B | £30.33B | £29.32B | £24.70B | £24.35B | £33.75B | £30.82B | £30.19B | £27.89B | £23.92B |
| Gross profit | £23.65B | £22.33B | £21.76B | £19.77B | £16.53B | £16.43B | £21.89B | £20.58B | £19.84B | £18.60B | £15.07B |
| Gross margin | 72.40% | 71.16% | 71.76% | 67.42% | 66.95% | 67.44% | 64.85% | 66.77% | 65.74% | 66.69% | 62.99% |
| Research & development | £7.53B | £6.40B | £6.22B | £5.49B | £5.02B | £4.79B | £4.57B | £3.89B | £4.48B | £3.63B | £3.56B |
| Operating expenses | £15.72B | £18.31B | £15.02B | £13.34B | £12.18B | £10.45B | £14.93B | £15.10B | £15.76B | £16.00B | £4.75B |
| Operating income | £7.93B | £4.02B | £6.75B | £6.43B | £4.36B | £5.98B | £6.96B | £5.48B | £4.09B | £2.60B | £10.32B |
| Operating margin | 24.28% | 12.82% | 22.24% | 21.94% | 17.64% | 24.55% | 20.62% | 17.79% | 13.54% | 9.32% | 43.15% |
| EBITDA | £10.25B | £6.57B | £9.04B | £8.58B | £6.48B | £8.03B | £9.29B | £7.34B | £6.01B | £4.37B | £11.95B |
| EBITDA margin | 31.36% | 20.95% | 29.80% | 29.26% | 26.24% | 32.97% | 27.54% | 23.81% | 19.91% | 15.68% | 49.96% |
| Net income | £6.29B | £2.95B | £5.31B | £15.62B | £5.10B | £6.39B | £5.27B | £4.05B | £2.17B | £1.06B | £8.37B |
| Net profit margin | 19.25% | 9.41% | 17.50% | 53.27% | 20.63% | 26.23% | 15.61% | 13.13% | 7.19% | 3.81% | 35.00% |
| Basic EPSper basic share | £1.41 | £0.63 | £1.22 | £3.71 | £1.10 | £1.44 | £0.94 | £0.74 | £0.31 | £0.19 | £1.74 |
| Diluted EPSper diluted share | £1.39 | £0.62 | £1.20 | £3.66 | £1.08 | £1.43 | £0.93 | £0.73 | £0.31 | £0.19 | £1.72 |
Owners
Reported major voting-rights holders
2.19%of voting rights
Dodge & CoxNotified Jun 24, 2026
View holders
| Holder | Voting rights |
|---|---|
Dodge & Cox | 2.19%Jun 24, 2026 · 88.82M votes |
These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: FCA National Storage Mechanism ↗Updated Sep 27, 2026
Insider buys & sells
Community posts
GSK presents Jideytro data supporting a potential first-line lung-cancer filing
GSK ($GSK) reported a 94% response rate for Jideytro in 94 evaluable patients with ROS1-positive advanced lung cancer who had not previously received a ROS1 tyrosine kinase inhibitor. In the single-arm Phase 1/2 ARROS-1 study, 90% were prog ...
